Inferra AI / Company / ADPT
Adaptive Biotechnologies Corp
ADPT · Health Care
Last earnings Jul 29, 2026
Key results
Revenuequarter
$58.9 million
” Recent Highlights • Revenue for the second quarter of 2025 was $58.9 million.
SEC original ↗Adaptive Biotechnologies Corp — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Conflicting figures recorded for this item — see “Conflicting figures” below.
• Recognized $5.5 million in MRD pharma regulatory milestone revenue.
SEC original ↗Adaptive Biotechnologies Corp — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Second Quarter 2025 Financial Results Revenue was $58.9 million for the quarter ended June 30, 2025, representing a 36% increase from the second quarter in the prior year.
SEC original ↗Adaptive Biotechnologies Corp — Earnings release (8-K exhibit)EX-99Aug 5, 2025
MRD revenuequarter
$49.9 million
MRD revenue was $49.9 million for the quarter, representing a 42% increase from the second quarter in the prior year.
SEC original ↗Adaptive Biotechnologies Corp — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Immune Medicine revenuequarter
$8.9 million
Immune Medicine revenue was $8.9 million for the quarter, representing a 13% increase from the second quarter in the prior year.
SEC original ↗Adaptive Biotechnologies Corp — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Interest expense from our revenue interest purchase agreement was $2.9 million in the second quarter of 2025, compared to $2.7 million in the second quarter of the prior year.
SEC original ↗Adaptive Biotechnologies Corp — Earnings release (8-K exhibit)EX-99Aug 5, 2025
AI analysis
Q2 2025 · reported Aug 5, 2025
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
The quarter in charts
Guidance ladder — revenue
Delivered vs the company's guided range
EX-99 · Aug 5, 2025 Guide as stated by the company; range and midpoint computed from the stated figure.
Segment mix
Business-unit revenue, as stated
Segment revenue figures as stated in the event record.
Headline figures
| Metric | Q2 2025 | Prior qtr | Year ago |
|---|---|---|---|
| Revenue | $58.9 million | — | — |
| MRD revenue | $49.9 million | — | — |
| Immune Medicine revenue | $8.9 million | — | — |
Guidance · company-stated
““With 42% MRD revenue growth, 37% clonoSEQ volume growth and positive MRD adjusted EBITDA, we’re raising our MRD revenue guidance and lowering total company cash burn targets.”
“• Raising full year 2025 MRD revenue guidance to a new range of $190 million to $200 million, implying annual growth of 31% to 37%.”
“• Reducing total company full year 2025 cash burn guidance to a new range of $45 million to $55 million.”
Primary outlook statements conflict; no label forced — evidence preserved.
Capital allocation
Convertible Senior Notes and Capped Call Transactions 0% Convertible Senior Notes Due 2031 On June 22, 2026, we issued $ 345.0 million in aggregate principal amount of 0 % convertible senior notes due 2031 (the Notes ).
What changed vs last quarter
- Guide midpoint vs latest-quarter revenue +222.6% computed from stated figures
Event summary
Adaptive Biotechnologies Reports Second Quarter 2025 Financial Results
Based on: Earnings release + parent 8-K + 10-Q — transcript not held
Guidance & outlook
Revenue: ““With 42% MRD revenue growth, 37% clonoSEQ volume growth and positive MRD adjusted EBITDA, we’re raising our MRD revenue guidance and lowering total company cash burn targets.”
Revenue: “• Raising full year 2025 MRD revenue guidance to a new range of $190 million to $200 million, implying annual growth of 31% to 37%.”
Company outlook: “• Reducing total company full year 2025 cash burn guidance to a new range of $45 million to $55 million.”
Revenue — Raised (“raising”)
““With 42% MRD revenue growth, 37% clonoSEQ volume growth and positive MRD adjusted EBITDA, we’re raising our MRD revenue guidance and lowering total company cash burn targets.”
Revenue — Raised (“Raising”)
“• Raising full year 2025 MRD revenue guidance to a new range of $190 million to $200 million, implying annual growth of 31% to 37%.”
Company outlook — Lowered (“Reducing”)
“• Reducing total company full year 2025 cash burn guidance to a new range of $45 million to $55 million.”
Primary outlook statements conflict; no label forced — evidence preserved.
Capital allocation
Convertible Senior Notes and Capped Call Transactions 0% Convertible Senior Notes Due 2031 On June 22, 2026, we issued $ 345.0 million in aggregate principal amount of 0 % convertible senior notes due 2031 (the Notes ).
SEC original ↗Adaptive Biotechnologies Corp — 10-Q Quarterly report10-QAug 4, 2026
The Notes will mature on July 1, 2031 , unless earlier converted, redeemed or repurchased.
SEC original ↗Adaptive Biotechnologies Corp — 10-Q Quarterly report10-QAug 4, 2026
If certain business combination transactions or de-listing events that constitute a Fundamental Change (as defined in the Indenture) occurs, then noteholders may require us to repurchase their Notes for cash.
SEC original ↗Adaptive Biotechnologies Corp — 10-Q Quarterly report10-QAug 4, 2026
The repurchase price will be equal to the principal amount of the Notes to be repurchased, plus any accrued and unpaid special interest and additional interest.
SEC original ↗Adaptive Biotechnologies Corp — 10-Q Quarterly report10-QAug 4, 2026
On June 22, 2026, we used $ 156.9 million of proceeds from the Notes offering to repurchase all Revenue Interests outstanding and satisfied all obligations under the Purchase Agreement, effectively terminating the Purchase Agreement.
SEC original ↗Adaptive Biotechnologies Corp — 10-Q Quarterly report10-QAug 4, 2026
Conflicting figures recorded for this item — see “Conflicting figures” below.
In connection with the termination and in accordance with Accounting Standards Codification Topic 470, Debt , we recorded a loss on debt extinguishment of $ 23.7 million in the loss on revenue interest liability extinguishment line item of the condensed consolidated statements of operations for the three and six months ended June 30, 2026.
SEC original ↗Adaptive Biotechnologies Corp — 10-Q Quarterly report10-QAug 4, 2026
Strategy & priorities
About Adaptive Biotechnologies Adaptive Biotechnologies (“we” or “our”) is a commercial-stage biotechnology company focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease.
SEC original ↗Adaptive Biotechnologies Corp — Earnings release (8-K exhibit)EX-99Aug 5, 2025
All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts and other matters regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations.
SEC original ↗Adaptive Biotechnologies Corp — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Management uses Adjusted EBITDA, including segment Adjusted EBITDA, to evaluate the financial performance of our business and segments and to evaluate the effectiveness of our strategies.
SEC original ↗Adaptive Biotechnologies Corp — Earnings release (8-K exhibit)EX-99Aug 5, 2025
The forward-looking statements in this report also include statements regarding our research and development efforts and other matters regarding our business strategies, use of capital, results of operations and financial position and plans and objectives for future operations.
SEC original ↗Adaptive Biotechnologies Corp — 10-Q Quarterly report10-QAug 4, 2026
Risks & headwinds
These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements.
SEC original ↗Adaptive Biotechnologies Corp — Earnings release (8-K exhibit)EX-99Aug 5, 2025
These risks, uncertainties and other factors are described under Risk Factors, Management's Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in the documents we file with the Securities and Exchange Commission from time to time.
SEC original ↗Adaptive Biotechnologies Corp — Earnings release (8-K exhibit)EX-99Aug 5, 2025
Legal Proceedings 39 Item 1A.
SEC original ↗Adaptive Biotechnologies Corp — 10-Q Quarterly report10-QAug 4, 2026
These risks, uncertainties and other factors are described under Risk Factors, Management s Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this report and in other documents we file with the Securities and Exchange Commission (the SEC ) from time to time.
SEC original ↗Adaptive Biotechnologies Corp — 10-Q Quarterly report10-QAug 4, 2026
Revenue We disaggregate our revenue from contracts with customers by business area and type of arrangement, as we believe this best depicts how the nature, amount, timing and uncertainty of our revenue and cash flows are affected by economic factors.
SEC original ↗Adaptive Biotechnologies Corp — 10-Q Quarterly report10-QAug 4, 2026
Commitments and Contingencies Legal Proceedings We are subject to claims and assessments from time to time in the ordinary course of business.
SEC original ↗Adaptive Biotechnologies Corp — 10-Q Quarterly report10-QAug 4, 2026
Conflicting figures
Revenue
$58.9 million
“” Recent Highlights • Revenue for the second quarter of 2025 was $58.9 million.”
$ 156.9 million
“On June 22, 2026, we used $ 156.9 million of proceeds from the Notes offering to repurchase all Revenue Interests outstanding and satisfied all obligations under the Purchase Agreement, effectively terminating the Purchase Agreement.”
Earnings deck slides
0 decks with slide viewAdaptive Biotechnologies Corp — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
32 documents- Q2 2026
- 10-QADPT
- 8-KADPT
- Q1 2026
- 8-KADPT
- 8-KADPT
- 8-KADPT
- 8-KADPT
- 10-QADPT
- Q4 2025
- 10-KADPT
- 8-KADPT
- 8-KADPT
- EX-99ADPT
- Q3 2025
- 8-KADPT
- 8-KADPT
- 10-QADPT
- Q2 2025
- 8-KADPT
- 8-KADPT
- 10-QADPT
- Q1 2025
- 8-KADPT
- 8-KADPT
- 10-QADPT
- Q4 2024
- 10-KADPT
- 8-KADPT
- Q3 2024
- 8-KADPT
- 10-QADPT
- Q2 2024
- 8-KADPT
- 10-QADPT
- Q1 2024
- 8-KADPT
- 8-KADPT
- 10-QADPT
- 8-KADPT
- 8-KADPT
- EX-99ADPT
Earnings releases
14 documentsPresentations
1 document- Q4 2025
- ADPTDeck
Transcripts
0 documentsNo transcripts for Adaptive Biotechnologies Corp are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.